Ardelyx
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 267
- Market Cap
- $1.4B
- Website
- http://www.ardelyx.com
- Introduction
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
- Conditions
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 72
- Registration Number
- NCT06553547
- Locations
- 🇺🇸
Texas Digestive Specialists, Harlingen, Texas, United States
🇺🇸Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 7
- Registration Number
- NCT06203444
- Locations
- 🇺🇸
DDSI, Oklahoma City, Oklahoma, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 150
- Registration Number
- NCT05905926
- Locations
- 🇺🇸
OSF Saint Francis Medical Center, Peoria, Illinois, United States
🇺🇸Maspons Pediatric Gastro, El Paso, Texas, United States
🇺🇸G & L Research, LLC, Foley, Alabama, United States
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
- Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Interventions
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 180
- Registration Number
- NCT05643534
- Locations
- 🇺🇸
Orlando Health, Inc.- APH Center for Digestive Health and Nutrition, Orlando, Florida, United States
🇺🇸OSF Saint Francis Medical Center, Peoria, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 109
- Registration Number
- NCT04780841
- Locations
- 🇺🇸
Horizon Research Group LLC, Coral Gables, Florida, United States
🇺🇸Panax Clinical Research LLC, Miami Lakes, Florida, United States
🇺🇸South Florida Research Phase I-IV; Inc., Miami Springs, Florida, United States
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
- Conditions
- Chronic Kidney Disease Requiring Chronic DialysisHyperphosphatemia
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 333
- Registration Number
- NCT04549597
- Locations
- 🇺🇸
South Florida Research Institute, Lauderdale Lakes, Florida, United States
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
- Conditions
- HyperphosphatemiaEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 172
- Registration Number
- NCT03988920
- Locations
- 🇺🇸
Ardelyx Site #509, Houston, California, United States
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
- Conditions
- Hyperphosphatemia
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 236
- Registration Number
- NCT03824587
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸US Renal Care Pine Bluff, Pine Bluff, Arkansas, United States
🇺🇸Southeast Renal Research, Beverly Hills, California, United States
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
- Conditions
- Hyperphosphatemia
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 1559
- Registration Number
- NCT03427125
- Locations
- 🇺🇸
Site 529, Bronx, New York, United States
🇺🇸Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 60
- Registration Number
- NCT03018067
- Locations
- 🇺🇸
Capital Nephrology Associates, PA, Cary, North Carolina, United States